Exeltis wins two awards from the gynaecology specialist group for “The Most Innovative Product” – for the Slinda® minipill as well as for DeflaGyn® for the treatment of unclear cervical smears. The company, which specialises in women’s health, comes in 4th place in the multispecialty ranking “Best Pharmaceutical Companies Germany” 2022 in the category “Large Individual, Medium-sized and International Companies”. In 2021, Exeltis was still in 8th place in the ranking. Infectopharm, Gedeon Richter and ALK-Abelló were ranked first this year.
For the specialist group of gynaecologists, Slinda® is the most innovative product of 2022 – both in the field of oral contraceptives and in gynaecology in general. In addition to reliable contraceptive protection, the estrogen-free pill with the progestogen drospirenone scores particularly well with a convincing safety profile and a favourable bleeding pattern. The main criteria cited by gynaecologists for their choice of oral contraceptive product were newness to the market (62%), innovative mode of action (39%) and few/no side effects (35%). In the treatment of cervical dysplasia with the winner DeflaGyn®, these choice criteria accounted for 51% (novelty), 49% (innovative mode of action) and 45% (few/no side effects) respectively. Slinda® and DeflaGyn® had already won the “Most Innovative Product” award from gynaecologists in the previous year.
Exeltis: Rethinking women’s healthcare
Exeltis Germany GmbH is a subsidiary of the Spanish family-owned company Insud Pharma, founded in 1977. As the German marketing and sales unit, Exeltis has been marketing generics (branded generics) of the parent company since 2020, specialising in women’s health. The portfolio includes preparations for oral and vaginal contraception, for urogenital health, for menopausal hormone therapy and for endometriosis. The product range is supplemented by nutritional supplements for those who wish to have children (for her and him) and during pregnancy. In this respect, the company covers the needs of the female target group from puberty to menopause.
For the treatment of unclear or dysplastic cervical smears with the DeflaGyn® medical device set, a new, sustainable applicator was introduced in July 2021; in December 2021, the indication was extended to HPV-induced cervical lesions.
With Slinda, Exeltis introduced the only contraceptive drospirenone monopreparation in Germany in May 2021. As a progestogen-only pill, Slinda can also be used by women who cannot tolerate oestrogens.
A new addition to the portfolio is Xonvea®, a medicinal product approved for the symptomatic treatment of nausea and vomiting during pregnancy (emesis).
The company, based in Ismaning near Munich in Bavaria, employs more than 80 people in the office and in the field. The annual turnover is in the range of 40-50 million euros. With “Gyn aktuell”, Exeltis offers an online specialist magazine for gynaecologists (www.exeltis.de/gyn-aktuell/).
The Exeltis Group has subsidiaries in 40 countries that market the pharmaceutical products of its parent company Insud Pharma. One of the advantages of this group of companies is that research, development and production are part of the international group, but marketing is characterised by the country-specific handwriting of the medium-sized subsidiaries. This allows Exeltis Germany GmbH to respond flexibly to the needs of its customers in the German market and at the same time benefit from the know-how of an internationally experienced manufacturer.
Multiple awards for Exeltis for innovative products
Exeltis has received the award “Most Innovative Product” several times, for the first time in 2021 for DeflaGyn® and Slinda® and for the second time in 2022 for the same preparations. Although Exeltis has only been on the market for 12 years, it is already one of the multiple winners in the Pharma Trend benchmark study.
17% of the gynaecology specialists chose the estrogen-free oral contraceptive Slinda® in the Pharma Trend Award “The most innovative product” in gynaecology. The decisive factors for the decision were for 76% of the respondents the novelty on the market, for 41% the innovative active principle and for 29% the good tolerability of the preparation, which is the first mini-pill to contain only the progestogen drospirenone.
In the award “The most innovative product” for the treatment of cervical dysplasia/erosions in the specialist group, 45% of the gynaecologists voted for the prescription medical device set DeflaGyn®. 69 of the 100 doctors justified their choice of DeflyGyn® with the novelty on the market, 56% with the innovative active principle. For 38%, the lack of side effects was an important criterion.
Awards for innovation and sustainability since 2000:
- Slinda® (2021, 2022)
- DeflaGyn® (2021, 2022)